Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperthermia + Tislelizumab in Advanced Gastrointestinal Tumours
NCT06022692Phase 2Completed
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastrointestinal tumor. Started Jun 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastrointestinal tumor
Beyond the preview
Go deeper on NCT06022692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022692.